These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 9263357

  • 1. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
    Wehmeier A, Südhoff T, Meierkord F.
    Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
    [Abstract] [Full Text] [Related]

  • 2. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M.
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract] [Full Text] [Related]

  • 3. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
    Murphy S.
    Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
    [Abstract] [Full Text] [Related]

  • 4. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH.
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [Abstract] [Full Text] [Related]

  • 5. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles.
    Petrides PE, Siegel F.
    Blood Cells Mol Dis; 2006 Sep; 36(3):379-84. PubMed ID: 16563815
    [Abstract] [Full Text] [Related]

  • 6. [Dysmegakaryocytopoiesis and dysthrombopoiesis in myeloproliferative syndromes].
    Brière J, Kiladjian JJ, Peynaud-Debayle E.
    C R Seances Soc Biol Fil; 1996 Sep; 190(5-6):533-9. PubMed ID: 9074718
    [Abstract] [Full Text] [Related]

  • 7. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [Abstract] [Full Text] [Related]

  • 8. Aspirin in essential thrombocythemia: status quo and quo vadis.
    Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ.
    Semin Thromb Hemost; 1997 Apr; 23(4):371-7. PubMed ID: 9263354
    [Abstract] [Full Text] [Related]

  • 9. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
    Wehmeier A, Daum I, Jamin H, Schneider W.
    Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
    [Abstract] [Full Text] [Related]

  • 10. [Blood platelet changes in myeloproliferative disorders].
    D'Angelo G, Calvano D, Giardini C.
    Minerva Med; 1988 Oct; 79(10):853-7. PubMed ID: 3141845
    [Abstract] [Full Text] [Related]

  • 11. [Platelet defects in chronic myeloproliferative disorders].
    Raszeja-Specht A, Skibowska A, Kabata J, Hellmann A.
    Acta Haematol Pol; 1994 Oct; 25(3):253-60. PubMed ID: 7992598
    [Abstract] [Full Text] [Related]

  • 12. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
    Murphy S, Davis JL, Walsh PN, Gardner FH.
    Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
    [Abstract] [Full Text] [Related]

  • 13. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease.
    Wehmeier A, Scharf RE, Fricke S, Schneider W.
    Haemostasis; 1989 Aug; 19(5):251-9. PubMed ID: 2777137
    [Abstract] [Full Text] [Related]

  • 14. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders.
    Pareti FI, Gugliotta L, Mannucci L, Guarini A, Mannucci PM.
    Thromb Haemost; 1982 Apr 30; 47(2):84-9. PubMed ID: 7101243
    [Abstract] [Full Text] [Related]

  • 15. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
    Landolfi R, Di Gennaro L, Novarese L, Patrono C.
    Semin Thromb Hemost; 2006 Apr 30; 32(3):251-9. PubMed ID: 16673279
    [Abstract] [Full Text] [Related]

  • 16. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HA, van Vliet HH.
    Platelets; 2006 Dec 30; 17(8):528-44. PubMed ID: 17127481
    [Abstract] [Full Text] [Related]

  • 17. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y.
    Oncologist; 1996 Dec 30; 1(4):284-287. PubMed ID: 10388004
    [Abstract] [Full Text] [Related]

  • 18. Platelet abnormalities in myeloproliferative disorders.
    Holme S, Murphy S.
    Clin Lab Med; 1990 Dec 30; 10(4):873-88. PubMed ID: 2272179
    [Abstract] [Full Text] [Related]

  • 19. Blood cells diseases and thrombosis.
    Leone G, Sica S, Chiusolo P, Teofili L, De Stefano V.
    Haematologica; 2001 Dec 30; 86(12):1236-44. PubMed ID: 11726314
    [Abstract] [Full Text] [Related]

  • 20. [Use of interferon in the treatment of chronic myeloproliferative disorders].
    Robak T.
    Acta Haematol Pol; 1992 Dec 30; 23(2 Suppl 1):30-7. PubMed ID: 1488870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.